Antihypertensive Potential and Mechanism of Action of Astaxanthin(3)Antioxidant and Histopathological Effects in Spontaneously Hypertensive Rats

  • Hussein Ghazi
    International Research Center for Traditional Medicine, Toyama Prefecture Division of Medicinal Pharmacology, Institute of Natural Medicine, University of Toyama
  • Goto Hirozo
    Department of Kampo Diagnostics, Institute of Natural Medicine, University of Toyama
  • Oda Shinobu
    Department of Kampo Diagnostics, Institute of Natural Medicine, University of Toyama
  • Sankawa Ushio
    International Research Center for Traditional Medicine, Toyama Prefecture
  • Matsumoto Kinzo
    Division of Medicinal Pharmacology, Institute of Natural Medicine, University of Toyama
  • Watanabe Hiroshi
    Division of Medicinal Pharmacology, Institute of Natural Medicine, University of Toyama

書誌事項

タイトル別名
  • Antihypertensive Potential and Mechanism of Action of Astaxanthin: III. Antioxidant and Histopathological Effects in Spontaneously Hypertensive Rats

この論文をさがす

説明

We investigated the effects of a dietary astaxanthin (ASX-O) on oxidative parameters in spontaneously hypertensive rats (SHR), by determination of the level of nitric oxide (NO) end products nitrite/nitrate (NO2/NO3) and lipid peroxidation in ASX-O-treated SHR. Oral administration of the ASX-O significantly reduced the plasma level of NO2/NO3 compared to the control vehicle (p<0.05). The lipid peroxidation level, however, was reduced in both ASX-O- and olive oil-treated groups. We also analyzed the post-treatment effects of ASX-O on the vascular tissues by examining the changes in the aorta and coronary arteries and arterioles. The dietary ASX-O showed significant reduction in the elastin bands in the rat aorta (p<0.05). It also significantly decreased the [wall : lumen] aerial ratio of the coronary arteries. These results suggest that ASX-O can modulate the oxidative condition and may improve vascular elastin and arterial wall thickness in hypertension.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (60)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ